GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings and unveiled a partnership with 23andMe Inc. (Mountain View, Calif.).

In a presentation, CEO Emma

Read the full 496 word article

User Sign In